Legis Daily

A bill to amend title XIX of the Social Security Act to prevent the misclassification of drugs for purposes of the Medicaid drug rebate program.

USA115th CongressS-3702| Senate 
| Updated: 12/4/2018
Ron Wyden

Ron Wyden

Democratic Senator

Oregon

Cosponsors (10)
Joni Ernst (Republican)Margaret Wood Hassan (Democratic)Catherine Cortez Masto (Democratic)Amy Klobuchar (Democratic)Robert P. Casey (Democratic)Debbie Stabenow (Democratic)Tina Smith (Democratic)Sherrod Brown (Democratic)Chuck Grassley (Republican)Richard Blumenthal (Democratic)

Finance Committee

  • Introduced
  • In Committee
  • On Floor
  • Passed Chamber
  • Enacted
Right Rebate Act of 2018 This bill requires drug manufacturers with Medicaid rebate agreements for covered outpatient drugs to disclose drug product information. Manufacturers are subject to civil penalties for knowingly misclassifying drugs. Manufacturers are also required to compensate for rebates that were initially underpaid as a result of misclassification (whether or not such misclassification was committed knowingly).
View Full Text

Suggested Questions

Get AI-generated questions to help you understand this bill better

Timeline
Dec 4, 2018
Introduced in Senate
Dec 4, 2018
Read twice and referred to the Committee on Finance.
Dec 13, 2018

Latest Companion Bill Action

HR 115-7223
Referred to the Subcommittee on Health.
  • December 4, 2018
    Introduced in Senate


  • December 4, 2018
    Read twice and referred to the Committee on Finance.


  • December 13, 2018

    Latest Companion Bill Action

    HR 115-7223
    Referred to the Subcommittee on Health.

Health

Related Bills

  • HR 115-7223: To amend title XIX of the Social Security Act to prevent the misclassification of drugs for purposes of the Medicaid drug rebate program.
  • HR 115-7217: IMPROVE Act
Business recordsCivil actions and liabilityHome and outpatient careInflation and pricesMedicaidPrescription drugsState and local government operations

A bill to amend title XIX of the Social Security Act to prevent the misclassification of drugs for purposes of the Medicaid drug rebate program.

USA115th CongressS-3702| Senate 
| Updated: 12/4/2018
Right Rebate Act of 2018 This bill requires drug manufacturers with Medicaid rebate agreements for covered outpatient drugs to disclose drug product information. Manufacturers are subject to civil penalties for knowingly misclassifying drugs. Manufacturers are also required to compensate for rebates that were initially underpaid as a result of misclassification (whether or not such misclassification was committed knowingly).
View Full Text

Suggested Questions

Get AI-generated questions to help you understand this bill better

Timeline
Dec 4, 2018
Introduced in Senate
Dec 4, 2018
Read twice and referred to the Committee on Finance.
Dec 13, 2018

Latest Companion Bill Action

HR 115-7223
Referred to the Subcommittee on Health.
  • December 4, 2018
    Introduced in Senate


  • December 4, 2018
    Read twice and referred to the Committee on Finance.


  • December 13, 2018

    Latest Companion Bill Action

    HR 115-7223
    Referred to the Subcommittee on Health.
Ron Wyden

Ron Wyden

Democratic Senator

Oregon

Cosponsors (10)
Joni Ernst (Republican)Margaret Wood Hassan (Democratic)Catherine Cortez Masto (Democratic)Amy Klobuchar (Democratic)Robert P. Casey (Democratic)Debbie Stabenow (Democratic)Tina Smith (Democratic)Sherrod Brown (Democratic)Chuck Grassley (Republican)Richard Blumenthal (Democratic)

Finance Committee

Health

Related Bills

  • HR 115-7223: To amend title XIX of the Social Security Act to prevent the misclassification of drugs for purposes of the Medicaid drug rebate program.
  • HR 115-7217: IMPROVE Act
  • Introduced
  • In Committee
  • On Floor
  • Passed Chamber
  • Enacted
Business recordsCivil actions and liabilityHome and outpatient careInflation and pricesMedicaidPrescription drugsState and local government operations